Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,672.50GBp
8:01am EDT
Change (% chg)

-7.50 (-0.45%)
Prev Close
1,680.00
Open
1,682.00
Day's High
1,686.00
Day's Low
1,659.00
Volume
332,945
Avg. Vol
809,941
52-wk High
2,703.00
52-wk Low
1,573.00

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.25
Market Cap(Mil.): £4,050.52
Shares Outstanding(Mil.): 240.38
Dividend: 18.00
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 33.16 14.29 17.36
EPS (TTM): 0.51 -- --
ROI: 5.83 -7.57 -5.72
ROE: 8.30 -7.17 -5.10

Hikma cuts revenue forecast on generic Advair delay; shares sink

Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

May 19 2017

UPDATE 2-Hikma cuts revenue forecast on generic Advair delay; shares sink

May 19 Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low.

May 19 2017

BRIEF-Hikma sees FY group revenue between $2.0-$2.1 bln at constant currency

* Expect full year group revenue to be in range of $2.0-$2.1 billion in constant currency in 2017

May 19 2017

Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

LONDON, May 11 Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application.

May 11 2017

RPT-BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

Apr 06 2017

BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

Apr 06 2017

BRIEF-Jazz Pharma settles Xyrem patent litigation with Hikma Pharma

* Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation

Apr 05 2017

BRIEF-Hikma sees 2017 revenue to be around $2.2 bln

* FY group revenue of $1,950 million, up 35% and up 39% in constant currency

Mar 15 2017

D.C. Circuit refuses to revive Takeda appeal to block rival gout drug

A federal appeals court has refused to revive Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates' bid to block Hikma Pharmaceuticals PLC from selling its gout drug Mitigare.

Feb 13 2017

BRIEF-Hikma signs licensing deal with Orion for asthma product

* Signed an exclusive licensing and distribution agreement with Orion Corporation Of Finland, for its new Easyhaler combination product

Feb 13 2017

More From Around the Web

Earnings vs. Estimates